Correlation Engine 2.0
Clear Search sequence regions


Sizes of these terms reflect their relevance to your search.

SARS-CoV-2, the causal agent of COVID-19, first emerged in late 2019 in China. It has since infected more than 870,000 individuals and caused more than 43,000 deaths globally. Here, we discuss therapeutic and prophylactic interventions for SARS-CoV-2 with a focus on vaccine development and its challenges. Vaccines are being rapidly developed but will likely come too late to affect the first wave of a potential pandemic. Nevertheless, critical lessons can be learned for the development of vaccines against rapidly emerging viruses. Importantly, SARS-CoV-2 vaccines will be essential to reducing morbidity and mortality if the virus establishes itself in the population. Copyright © 2020 Elsevier Inc. All rights reserved.

Citation

Fatima Amanat, Florian Krammer. SARS-CoV-2 Vaccines: Status Report. Immunity. 2020 Apr 14;52(4):583-589

Expand section icon Mesh Tags

Expand section icon Substances


PMID: 32259480

View Full Text